Literature DB >> 31046976

IgG4-Related Disease with Emphasis on Its Gastrointestinal Manifestation.

Bijal Vashi1, Arezou Khosroshahi2.   

Abstract

IgG4-related disease is an immune-mediated fibroinflammatory condition with a diverse spectrum of organ involvement, commonly in the pancreas and bile ducts among other organs such as salivary and lacrimal glands. Classic histopathologic findings are the gold standard for confirmation of diagnosis, although diagnosis remains challenging, as biomarkers to date are neither sufficient nor necessary. Glucocorticoids are the most effective initial treatment, generally having a dramatic response, although limited clinical evidence exists regarding effective maintenance therapy. This review summarizes key GI manifestations of this condition for the practicing gastroenterologist and addresses the pathology, disease mechanism, and current therapeutic recommendations.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune pancreatitis; Cholangitis; IgG4; IgG4-RD; Rituximab

Mesh:

Substances:

Year:  2019        PMID: 31046976     DOI: 10.1016/j.gtc.2019.02.008

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  3 in total

1.  Early pancreatic cancer in IgG4-related pancreatic mass: A case report.

Authors:  Juan Glinka; Francisco Calderón; Martín de Santibañes; Sung Ho Hyon; Adrián Gadano; Eduardo Mullen; Melina Pol; Juan Spina; Eduardo de Santibañes
Journal:  World J Gastrointest Surg       Date:  2019-12-27

Review 2.  Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations.

Authors:  Dimitri Poddighe
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

3.  Localized IgG4-related disease manifested on the tongue: a case report.

Authors:  Helya Hashemi; Andreas Thor; Erik Hellbacher; Marie Carlson; Miklós Gulyás; Lena Blomstrand
Journal:  Ups J Med Sci       Date:  2021-05-12       Impact factor: 2.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.